Progress in the development of prognostic and predictive markers for gastrointestinal malignancies

被引：17

作者：

Denlinger C.S. ^{[1
]}

Cohen S.J. ^{[1
]}

机构：

[1] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA

来源：

Current Treatment Options in Oncology | 2007年 / 8卷 / 5期

关键词：

Overall Survival; Epidermal Growth Factor Receptor; Gemcitabine; Clin Oncol; Cetuximab;

D O I：

10.1007/s11864-007-0045-x

中图分类号：

学科分类号：

摘要：

Gastrointestinal cancers remain a significant cause of morbidity and mortality. While increasing therapeutic options have improved outcomes for many patients, they have also complicated treatment decision-making. Unfortunately, most patients with advanced gastrointestinal malignancies die from their disease. Prognostic and predictive markers could improve treatment significantly by identifying patients who may or may not require a given therapy, and determining those most likely to benefit from a therapy. Candidates for such markers include blood antigens and circulating tumor cells, tumor enzyme and gene expression, and pharmacodynamic endpoints. In this review, we summarize reported and ongoing research to define and validate prognostic and predictive markers in gastrointestinal malignancies, with an emphasis on colorectal cancer and brief overview of pancreatic and neuroendocrine tumors. © Current Science Inc. 2008.

引用

页码：339 / 351

页数：12

共 88 条

[71]

Moroni M., Veronese S., Benvenuti S., Et al., Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study, Lancet Oncol, 6, 5, pp. 279-286, (2005)

[72]

Khambata-Ford S., Garrett C.R., Meropol N.J., Et al., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 22, pp. 3230-3237, (2007)

[73]

Lenz H.J., Van Cutsem E., Khambata-Ford S., Et al., Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines, J Clin Oncol, 24, 30, pp. 4914-4921, (2006)

[74]

Lievre A., Bachet J.B., Le Corre D., Et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 66, 8, pp. 3992-3995, (2006)

[75]

Van Cutsem E., Peeters M., Siena S., Et al., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer, J Clin Oncol, 25, 13, pp. 1658-1664, (2007)

[76]

Amado R.G., Wolf M., Freeman D., Et al., Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy, Euro J Cancer, 5, 6 S, (2007)

[77]

Ferrone C.R., Finkelstein D.M., Thayer S.P., Muzikansky A., Fernandez-delCastillo C., Warshaw A.L., Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma, J Clin Oncol, 24, 18, pp. 2897-2902, (2006)

[78]

Berger A.C., Winter K., Hoffman J., Et al., Post-resection CA 19-9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704, J Clin Oncol, 25, 18 SUPPL., (2007)

[79]

Ko A.H., Hwang J., Venook A.P., Abbruzzese J.L., Bergsland E.K., Tempero M.A., Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer, Br J Cancer, 93, 2, pp. 195-199, (2005)

[80]

Nakano Y., Tanno S., Koizumi K., Et al., Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells, Br J Cancer, 96, 3, pp. 457-463, (2007)

← 1 2 3 4 5 6 7 8 9 →